Determination of amikacin stability at 1% and 3% concentrations in four topical solutions over a 56-day period.

Autor: Klinczar AM; Animal Dermatology Clinic, Marietta, GA, 30067, USA., Griffies JD; Animal Dermatology Clinic, Marietta, GA, 30067, USA., Bateman FL; Animal Dermatology Clinic, Marietta, GA, 30067, USA., Arnold RD; Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, 257 Pharmacy Research Building, Auburn, AL, 36849, USA., Jasper SL; Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, 257 Pharmacy Research Building, Auburn, AL, 36849, USA., Brown AR; Department of Statistics and Analytical Sciences, Kennesaw State University, 257 Kennesaw State Univ Rd NW, Kennesaw, GA, 30144, USA.
Jazyk: angličtina
Zdroj: Veterinary dermatology [Vet Dermatol] 2022 Feb; Vol. 33 (1), pp. 23-e8. Date of Electronic Publication: 2021 Sep 20.
DOI: 10.1111/vde.13025
Abstrakt: Background: Anecdotally, amikacin has been added to compounded topical preparations for the management of canine bacterial otitis externa. However, the stability of amikacin within these solutions is unknown.
Hypothesis/objectives: The purpose of this study was to determine the stability of amikacin at 10 and 30 mg/mL concentrations in four topical solutions over a 56 day period. We hypothesised that amikacin would maintain chemical stability within the various solutions.
Methods and Materials: Amikacin was formulated to 10 and 30 mg/mL (1% and 3%) concentrations within four topical solutions: tris-EDTA (TrizEDTA Aqueous Flush) (TE); 0.15% chlorhexidine gluconate and tris-EDTA (TrizCHLOR Flush) (TC); 0.9% NaCl (NA); and 0.9% NaCl + 2 mg/mL dexamethasone (ND). Samples were made in duplicate and stored at room temperature (25°C) for 0, 7,14, 21, 28 and 56 days. Amikacin content was quantified, in triplicate, by ultrahigh-performance liquid chromatography tandem mass spectrometry.
Results: The recovered amikacin concentrations for the 10 mg/mL solutions ranged from 10 to 13.5 mg/mL (mean 11.5 mg/mL) with the exception of NA sample 2 at Day (D)0 (9.4 mg/mL) and D7 (9.2 mg/mL). The recovered amikacin concentrations for the 30 mg/mL solutions ranged from 30 to 40.2 mg/mL (mean 35.7 mg/mL). No significant difference was seen between the amikacin concentrations at D0 compared to D56 for all solutions except 10 mg/mL TE (P < 0.001).
Conclusions and Clinical Relevance: Amikacin maintained stability within TE, TC, NA and ND over 56 days except when formulated at 10 mg/mL within TE.
(© 2021 ESVD and ACVD.)
Databáze: MEDLINE
Externí odkaz: